Francis A. Drobniewski - Infectious Diseases

Author Information

Francis A. Drobniewski is a distinguished researcher affiliated with multiple prestigious institutions in the UK. He is associated with the National Mycobacterium Reference Laboratory at Public Health England, the Centre for Immunology and Infectious Disease at Queen Mary University of London, and the Department of Infectious Diseases at Imperial College. His work spans several facets of infectious diseases, emphasizing tuberculosis and its intersection with other health conditions.

Research Contributions

Francis A. Drobniewski has made significant contributions to the understanding and management of infectious diseases, particularly tuberculosis (TB) and COVID-19. His research includes exploring vaccine hesitancy in diverse populations, innovations in diagnostic methods for mycobacterial infections, and the interplay between chronic diseases and TB. His work on lipid fingerprint-based diagnosis using MALDI-TOF and the exploration of genetic markers of treatment success highlights his commitment to advancing diagnostic and therapeutic strategies in infectious diseases.

Aliases

Francis A. Drobniewski is known by several aliases in academic publications, including F. A. Drobniewski, F A Drobniewski, F. Drobniewski, and Francis Drobniewski. These variations may appear in different publications, reflecting common naming conventions in scientific literature.

Publication and Citation Metrics

Metric	Value
Total Citation Count	15,154
h-index	61
Total Number of Papers	300

Publications:

COVID-19 Vaccine Hesitancy in Diverse Groups in the UK—Is the Driver Economic or Cultural in Student Populations

DOI: 10.3390/vaccines10040501

Year: 2022

An Improved Method for Rapid Detection of Mycobacterium abscessus Complex Based on Species-Specific Lipid Fingerprint by Routine MALDI-TOF

DOI: 10.3389/fchem.2021.715890

Year: 2021

COVID-19 vaccine hesitancy in diverse groups in the UK - is the driver economic or cultural in student populations?

DOI: 10.1101/2021.12.14.21267773

Year: 2021

COVID-19 and Tuberculosis—A Global Tale of Hubris and Lessons Unlearned?

DOI: 10.3389/fmed.2021.799640

Year: 2021

Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles

DOI: 10.1002/jev2.12046

Year: 2021

SUN-117 CHRONIC KIDNEY DISEASE AND NON-COMMUNICABLE DISEASES IN TUBERCULOSIS PATIENTS OF SUNSARI DISTRICT IN EASTERN NEPAL AND ITS ASSOCIATED FACTORS

DOI: 10.1016/j.ekir.2020.02.644

Year: 2020

Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution

DOI: 10.1186/s12866-020-01954-w

Year: 2020

Performance of lipid fingerprint-based MALDI-ToF for the diagnosis of mycobacterial infections

DOI: 10.1016/j.cmi.2020.08.027

Year: 2020

GenomegaMap: Within-Species Genome-Wide dN/dS Estimation from over 10,000 Genomes

DOI: 10.1093/molbev/msaa069

Year: 2020

Biomarkers of treatment success in fully sensitive pulmonary tuberculosis patients: a multicenter longitudinal study.

DOI: 10.2217/bmm-2020-0246

Year: 2020

What is West Nile Virus?

What Are the Challenges in Controlling Culex Mosquitoes?

What are the Challenges in Controlling Anopheles Mosquitoes?

Why is Prevalence Important?

What are the Future Directions in Antimicrobial Therapies?

What are the Clinical Implications of Targeting Folate Biosynthesis?

What are Common Infectious Diseases?

How is Herpes Diagnosed?

Can Colonization Lead to Infection?

What are the Symptoms of West Nile Virus?

Partnered Content Networks

Relevant Topics